In the continuation group, Grade 1 or 2 treatment‐related adverse events due to any cause included fatigue, pruritus, adrenal insufficiency syndrome, elevated AST/ALT, elevated bilirubin, constipation, albumin reduction, hyponatremia, and increased blood pressure. The gene discussed is GPT; the disease is Hyponatremia.